Important safety note: Because retatrutide is unlicensed in the UK, there is no MHRA-approved Summary of Product Characteristics or monitoring recommendations for routine clinical use, and there is no regulated supply chain
The reduction in hepatic steatosis occurred alongside improvements in liver enzymes, with ALT and AST levels declining from baseline, indicating reduced hepatocellular inflammation and improved liver health
Its one of the most efficient, natural-looking methods available today
The phase 2 and phase 3 clinical trials used the same starting dose for all weight groups
[19] [20] Factors that increase bleeding risk include advanced age (65 years), history of bleeding, uncontrolled hypertension, labile INR (for warfarin users), concomitant antiplatelet therapy, excessive alcohol use, and certain comorbidities